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ABSTRACT 
Hypertension complicates up to 10% of pregnancies, globally. Pregnancy hypertension is defined as 
systolic blood pressure (BP) ≥140mmHg or a diastolic BP ≥90mmHg, based usually on measurements in 
office/clinic settings and using a wide variety of BP devices. The hypertensive disorders of pregnancy 
(HDPs) are classified into: (i) chronic hypertension diagnosed before pregnancy or 20 weeks’ gestation; 
(ii) gestational hypertension diagnosed at ≥20 weeks; and (iii) preeclampsia, defined restrictively as 
gestational hypertension with proteinuria or broadly as gestational hypertension with proteinuria or an 
end-organ manifestation consistent with preeclampsia. Absolute BP values ≥140/90mmHg are 
associated with elevated maternal and perinatal risk, particularly with preeclampsia. This review will 
focus on antihypertensive therapy of the HDPs as a specific management strategy. Underpinning this 
therapy is the need for accurate measurement of BP, agreed-upon classification of pregnancy 
hypertension, agreed-upon BP thresholds for enhanced surveillance and antihypertensive treatment, 
and collaborative teamwork in management. Challenges relate to the methodology of studies upon 
which care is based, as well as aspects of the care itself, particularly the unregulated use of home BP 
monitoring. Pitfalls include the unsubstantiated belief that nifedipine and magnesium sulfate cannot be 
used together, and the perception that severe hypertension and non-severe hypertension are separate 
entities rather than lying along a spectrum of BP values. The following must be addressed by future 
research: guidance for nuanced care as women transition between severe and non-severe hypertension, 
personalized antihypertensive therapy, and incorporation of women’s values into research priorities and 
clinical practice when antihypertensive care is chosen. 
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Abbreviations:  
 ACE inhibitor= angiotensin converting enzyme inhibitor 
 ACOG = American College of Obstetrics and Gynecology 
 aOR = adjusted odds ratio 
 ARB = (angiotensin receptor blocker 
 BP  = blood pressure 
 FHR = fetal heart rate 
 HDP = hypertensive disorder of pregnancy 
 IQ = intelligence quotient 
 ISSHP = International Society for the Study of Hypertension in Pregnancy 
 LMIC = low-and-middle-income country 
 RCT = randomized controlled trial 
 SGA= small for gestational age 
 SMFM = Society of Maternal-Fetal Medicine 
 
GENERAL INTRODUCTION 
Hypertension complicates up to 10% of pregnancies, globally. Pregnancy hypertension is defined as 
systolic blood pressure (BP) ≥140mmHg or a diastolic BP ≥90mmHg, based usually on measurements in 
office/clinic settings and using a wide variety of BP devices and BP thresholds that correspond to two 
standard deviations above the mean BP throughout pregnancy. 1-3 
The hypertensive disorders of pregnancy (HDPs) are classified into three primary types: (i) chronic 
hypertension diagnosed before pregnancy or before 20 weeks’ gestation; (ii) gestational hypertension 
diagnosed at ≥20 weeks; or (iii) preeclampsia, defined restrictively (and historically) as gestational 
hypertension with proteinuria or broadly as gestational hypertension with either proteinuria or an end-
organ manifestation consistent with preeclampsia (Table 1). 4;5 There is widespread agreement on 
definitions other than for preeclampsia.6  
Preeclampsia is in the differential diagnosis of any hypertension from 20 weeks’ gestation. First, up to 
25% of women with chronic hypertension may develop superimposed preeclampsia, and up to 35% with 
gestational hypertension (especially with onset at <34 weeks) may progress to preeclampsia.7;8 Second, 
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preeclampsia is the HDP associated with the greatest risk of complications, involving virtually any organ 
system to effect adverse outcomes through endothelial cell dysfunction and the hypertension itself. 
Finally, preeclampsia management is more than solely antihypertensive therapy (Table 1),5 mandating 
close interspecialty collaboration.4  
The HDPs, especially preeclampsia, is associated with elevated maternal and perinatal risk. 
Antihypertensive treatment of elevated BP, in the range of 140-159/90-109mmHg and to a goal of 
85mmHg diastolic, is associated with maternal benefit without increasing perinatal risk.9 This approach 
applies to all HDPs and gestational age at presentation with hypertension. Of note, BP values 
≥160/110mmHg, regardless of the HDP, constitute a medical urgency requiring antihypertensive 
therapy;4;6 more-resourced settings are focused on determining the best initial treatment, bundling 
antihypertensive therapy with other aspects of management.  
This review will focus on antihypertensive therapy of the HDPs as a specific strategy within broader 
management that includes preeclampsia prevention among women with chronic hypertension and 
preeclampsia management.5  
 
CLINICAL NEEDS IN THIS FIELD 
• Accurate measurement of BP 
BP measurement techniques are the same in and outside pregnancy, including positioning and correct 
cuff size.10 However, the choice of the BP device used is context-sensitive.  
The general withdrawal of mercury sphygmomanometers has left maternity care providers with the 
choice of using aneroid or automated devices. (An accurate liquid crystal sphygmomanometer has been 
developed, but is not yet widely available.)11 Up to 50% of aneroid devices give inaccurate BP readings 
>10 mmHg through failure to maintain six-monthly calibration and resultant calibration drift; whereas 
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the same error occurs in only 10% of mercury devices.12 Also, many automated devices are inaccurate in 
pregnancy and most are inaccurate in preeclampsia;13 on average, underreading by 5 mmHg in systolic 
and diastolic, although there is wide variation.14 A list of validated devices is available online 
[http://www.dableducational.org/index.html]; to date, few have been validated for use in pregnancy or 
preeclampsia specifically.   
Out-of-office measurements, particularly self-measurements at home, should play a key role in 
diagnosis of hypertension in pregnancy, as in non-pregnancy; however, self-measurement is largely 
driven by patient interest. The widespread, largely unregulated, use of personal devices is a major 
challenge for maternity care (as discussed below).  
• Agreed-upon classification of the HDPs 
There is widespread consensus that both systolic and diastolic BP should be included in the definition of 
hypertension in pregnancy, although a few societies use only the diastolic criterion.6 The International 
Society for the Study of Hypertension in Pregnancy (ISSHP) has emphasized the need to repeat BP 
measurement over a few hours to confirm hypertension, or in 15 minutes if BP is severely elevated (i.e., 
systolic BP ≥160mmHg or diastolic BP ≥110mmHg).4  
In pregnancy there are no designations of either ‘elevated BP’ (i.e., systolic BP 120-129mmHg with 
diastolic BP <80mmHg) or Stage 1 hypertension (i.e., BP of 130-139/80-89mmHg) as designated outside 
pregnancy.10  
By non-pregnancy standards, defining severe hypertension from a systolic BP of 160mmHg is low. This 
threshold was established based on risk identified in an influential case series of women with stroke in 
pregnancy.15 It is unclear whether pregnant women with hypertension are more susceptible to stroke 
because hypertension can develop very quickly or because of the endothelial dysfunction of 
preeclampsia, but it is clear that autoregulation and BP level are not closely related.16  
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The ISSHP classifies the HDPs into groups depending on when in pregnancy elevated BP is documented, 
whether it is persistent, and whether there are features suggestive of preeclampsia (Table 2). ISSHP 
guidelines differ from some national guidelines by formally recognizing white-coat, masked, and 
transient hypertension as distinct entities.  
The internal medicine community is familiar with white-coat hypertension, and it should be managed in 
a similar way as outside pregnancy, relying on out-of-office measurements to guide antihypertensive 
therapy when women are outpatients. However, when women become inpatients (including for labor 
and delivery), clinicians have no choice but to treat BP measurements taken in hospital. While the 
medical community should also be familiar with masked hypertension, and would seek out-of-office BP 
measurement in the face of unexplained chronic kidney disease, for example, maternity care providers 
are unlikely to seek out-of-office BP measurements in the face of unexplained pregnancy complications 
that could be attributable to the HDPs (e.g., fetal growth restriction).  
ISSHP has emphasized the importance of transient hypertension, because it is not just elevated BP that 
was demonstrable because of poor measurement technique. Rather, transient gestational hypertension 
is associated with a 40% risk of developing true gestational hypertension or preeclampsia at some point 
in that pregnancy, mandating close follow-up.4   
• Agreed-upon thresholds for action 
For the mother, any hypertension is associated with more adverse outcomes, in virtually any organ 
system 17, from pulmonary edema and acute kidney injury, to central nervous system complications, 
including stroke 18;19. Both systolic and diastolic BP are important predictors of stroke, although variably 
associated.15;20 Also, the HDPs remain a leading causes of maternal death globally.  
For the fetus/newborn, the HDPs are associated with stillbirth, neonatal death, and neonatal morbidity 
of various severity (depending on gestational age at birth and fetal growth).  
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While studies have evaluated BP as a continuous measure, recent data from the CHIPS trial of women 
with chronic or gestational hypertension show that development of severe hypertension among women 
with prior non-severe hypertension is associated with elevated risk for both mother and baby, 
independently of any concomitant preeclampsia.9  
• Close collaboration with maternity care colleagues 
Standardized care and teamwork are particularly relevant during maternity care, a brief scenario by 
other medical standards (i.e., maximum duration of nine months of pregnancy and six weeks 
postpartum), and often delivered by many individuals with different skill sets. Standardization of 
complex care has been particularly topical within maternity services in the United States, given the 
upturn in maternal mortality, one of the leading causes of which is the HDPs (alongside postpartum 
hemorrhage and obstetric sepsis). ‘Bundles’ of complex care include management of severe 
hypertension 21. The bundle goes beyond the ‘response’ of antihypertensive therapy and both escalation 
measures for those unresponsive to standard treatment and postpartum follow-up, to reporting and 
systems learning, readiness, and recognition and prevention.  
 
SCIENTIFIC OVERVIEW OF PRECLINICAL AND CLINICAL STUDIES 
Antihypertensive treatment of hypertension in pregnancy is guided by many randomized controlled 
trials (RCTs), although most have been small and many of low quality.22;23 These trials have enrolled 
women with a variety of hypertensive disorders, although when women were enrolled at ≥20 weeks’ 
gestation, trials often did, or could, not distinguish between women with chronic hypertension and 
women with gestational hypertension or preeclampsia that, by definition, arose ≥20 weeks. Thus, the 
global guideline consensus is that clinicians respond to absolute BP levels, regardless of the underlying 
HDP.  
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The implications of hypertension for the mother and baby depend both on the absolute level of BPand 
the rate with which it has risen. An abrupt increase in intraluminal pressure may result in mechanical 
distension of the cerebral vessel wall and structural damage, as, in cats, an abrupt (vs. step-wise) 
increase in BP is associated with greater cerebrovascular permeability - a measure of vascular injury.24  
• Antihypertensive treatment of severe hypertension (BP ≥160/110mmHg) 
Consistently, national and international guidance recommends that severe hypertension in pregnancy 
requires antihypertensive therapy to avoid acute cerebrovascular complications, particularly stroke 6;25.  
As in the non-pregnant state, severe hypertension unassociated with end-organ complication is usually a 
medical ‘urgency’; and BP can be lowered over hours. In contrast, women with an end-organ 
complication(s), such as pulmonary edema or acute kidney injury, should have their BP lowered over a 
shorter time frame; to be conservative, women with headache and visual symptoms should be regarded 
as having end-organ complications.18  
As for non-pregnancy, the goal should be lowering to non-severe levels (i.e., <160/110mmHg) over 
hours without reducing it by more than 25% initially, with subsequent gradual lowering over hours 
thereafter. The fetoplacental unit, which does not autoregulate blood flow, is at risk of underperfusion 
during this time; appropriate fetal heart rate (FHR) monitoring should be instituted by the obstetrician 
or his/her designate. The intravascular volume depletion of preeclampsia can precipitate hypotension 
following short-acting antihypertensive agent administration.  
Antihypertensive treatment of severe hypertension in pregnancy is guided by 52 RCTs (4588 women) of 
one short-acting antihypertensive vs. another, usually parenterally administered (other than of oral 
nifedipine.)26-33 Most published trials have compared parenteral hydralazine (usually 5mg iv) with either 
calcium channel blockers (usually nifedipine 10mg capsules orally) or parenteral labetalol (usually 20mg 
iv) with repeat doses administered every 15-20 minutes in order to achieve BP control in at least 80% of 
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women; in 10 trials, hydralazine was compared with drugs available only regionally or used infrequently. 
These dosing regimens are more conservative than those recommended by the American College of 
Obstetrics and Gynecology (ACOG) which advises that clinicians administer the drugs in escalating doses 
to achieve the target BP goals.34  
Hydralazine may be a less effective antihypertensive and associated with more maternal side effects, 
compared with calcium channel blockers. Hydralazine may be a more effective antihypertensive but 
associated with more maternal hypotension and side effects, compared with parenteral labetalol. Most 
of the published hydralazine trials were included in a 2003 meta-analysis that compared hydralazine 
with all other short-acting antihypertensive agents taken together; hydralazine was associated with 
more adverse effects, including maternal hypotension, Cesarean delivery, and adverse FHR effects.27 It 
should be noted that in two hydralazine vs. labetalol trials, parenteral labetalol was associated with 
more neonatal bradycardia (which required intervention in one of six affected babies in one trial). 
Oral nifedipine and parenteral nicardipine appear to be similarly effective for BP control compared with 
parenteral labetalol.32;33 The nifedipine preparations that are appropriate for treatment of severe 
hypertension are the capsule and the intermediate-acting (PA) tablet,35 where available. Most authors 
did not specify whether nifedipine capsules were bitten (prior to swallowing), which may have a greater 
effect on BP. The 10mg tablet may be associated with less maternal hypotension than the 10mg capsule 
when it is bitten/punctured 35;36. The 5 mg capsule may reduce the risk of a precipitous fall in BP.37;38 The 
effectiveness of nifedipine may be enhanced by concomitant vitamin D39 or, postnatally, by concomitant 
furosemide.40  
As most women with severe hypertension in pregnancy have a hypertensive ‘urgency’ that could be 
treated with oral agents, those (in addition to nifedipine discussed above) that lower BP over hours 
could be used. Although there are limited trial data evaluating this approach,31;41 oral labetalol (200mg) 
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has been used with good effect as part of a regional preeclampsia protocol in which treatment was 
successful in about half of women42 or in comparison with oral nifedipine;31 this approach is 
recommended as the first-line agent in the UK.43 The results of an oral nifedipine (tablet), labetalol, and 
methyldopa trial will report in 2018 (NCT01912677). While evidence is lacking, oral labetalol may also be 
useful to administer prior to sending a woman into hospital or arranging for her transport there for 
further management.44  
Drugs used both infrequently, often for refractory hypertension during critical care, include clonidine 
and captopril,29 nitroglycerin infusion, mini-dose diazoxide, and sodium nitroprusside.14 The latter may 
cause fetal cyanide toxicity and stillbirth.45  
In summary, oral nifedipine, parenteral hydralazine, and parenteral labetalol are the most commonly 
studied antihypertensive agents for severe hypertension. As none is clearly superior, each is a 
reasonable choice, in doses listed in Table 1. Some antihypertensives may be more or less appropriate 
based on associated medical conditions (such as poorly-controlled asthma) or therapies (such as current 
treatment with full doses of labetalol).  
The antihypertensives discussed here can be used with other medications. Nifedipine can be used 
together with magnesium sulfate as neuromuscular blockade in this setting is rare.46 Magnesium sulfate 
is not an effective antihypertensive agent, although it can cause a transient, mild decrease in BP.47  
Antihypertensive therapy for non-severe hypertension (BP 140-159/90-109mmHg) 
  Choice of antihypertensive agent in early pregnancy 
Women with chronic hypertension will be treated with antihypertensive therapy before or in early 
pregnancy. Teratogenicity (i.e., increased risk of major birth defects) and miscarriage risk should be 
considered and a decision made as to whether therapy should be discontinued or switched to another 
agent before pregnancy. Approximately half of pregnancies are unplanned; prescribers must consider 
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the potential for pregnancy in all hypertensive women of reproductive age. If medication is to be 
discontinued or replaced prepregnancy, a further consideration is that conception may normally take up 
to 12 months, and women over 30 years of age suffer more subfertility. Therefore, women could be off 
their medication for some time; when renoprotection is the goal, timelines are suboptimal. In addition, 
women who have had an inadvertent first trimester exposure to antihypertensive therapy should be 
counseled about their risks.  
Based on limited literature, most antihypertensives do not increase the risk of major malformations 
above the baseline risk of 1-5%, or the miscarriage rate of up to 20%. This concept of baseline risk is 
critical to communicate, as many women assume that their risk of early pregnancy problems is zero if                     
they do not take medication.  
No antihypertensive medication is a proven human teratogen. Initial associations between angiotensin 
converting enzyme (ACE) inhibitors and birth defects may have suffered from residual confounding.48 
Subsequent work has been variably reassuring. ACE inhibitors or angiotensin receptor blockers (ARBs) 
have been associated with miscarriage (but not birth defects) in a prospective cohort study of 138 
women, compared with both hypertension and normal pregnancy controls; most of the women (79.8%) 
were exposed to ACE inhibitors (usually ramipril, lisinopril, or enalapril) rather than ARBs.49 ACE 
inhibitors, ARBs, and other antihypertensive agents have been associated with teratogenicity in a meta-
analysis of five controlled cohort studies (786 infants exposed to ACE inhibitors or ARBs, 1723 exposed 
to other antihypertensives, and 1,091,472 unexposed).50 UK clinical practice guidelines state that 
thiazides are teratogenic, but a reference was neither provided nor identified.43  
In summary, given the lack of consistent and high-quality literature, it is considered acceptable to 
continue antihypertensive agents, including ACE inhibitors and ARBs, until conception.  
  Threshold for treatment in ongoing pregnancy 
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There have long been concerns that antihypertensive treatment of non-severe hypertension would 
decrease uteroplacental perfusion and fetal nutrition, leading to adverse fetal and newborn outcomes; 
an argument strengthened by a metaregression analysis that associated greater antihypertensive-
induced falls in mean arterial pressure with decreased fetal growth velocity.51;52 The CHIPS trial (Control 
of Hypertension In Pregnancy Study) tested this hypothesis.9  
CHIPS was a large definitive trial that provided evidence that non-severe hypertension in pregnancy 
should be treated with antihypertensive therapy 9. CHIPS enrolled women with chronic (75%) or 
gestational (25%) hypertension, but superimposed preeclampsia developed in almost half of women, 
and they continued to receive the BP treatment to which they were randomized for two subsequent 
weeks prior to delivery; therefore, it is reasonable to apply the results to all hypertensive pregnant 
women. Women with co-morbidities such as renal disease and pre-gestational diabetes were excluded; 
‘tight’ control is advocated for them to reduce progression of renal disease and long-term cardiovascular 
risk, as outside pregnancy.10 ‘Tight’ BP control (target diastolic BP 85mmHg) (vs. ‘less tight’ control, 
target diastolic BP 100mmHg) achieved a significantly lower BP by 6/5mmHg, through use of a simple 
treatment algorithm for ‘tight’ control that resulted in a mean BP of 133/85mmHg; antihypertensive 
therapy was decreased if diastolic BP fell below 80mmHg, as is frequently encountered with the mid-
pregnancy fall in BP.9 ‘Tight’ (vs. ‘less tight’) control resulted in similar rates of the adverse perinatal 
outcomes and birth weight <10th percentile. However, ‘tight’ (vs. ‘less tight’) control resulted in fewer 
adverse maternal outcomes of severe maternal hypertension, platelet count <100x109/L, and 
symptomatic elevated liver enzymes; there was no difference in serious maternal (end-organ) 
complications. Post-hoc analyses determined that severe hypertension, independent of any associated 
preeclampsia, was a risk factor for complications for the mother and the baby, and in the ‘less tight’ 
control arm specifically, severe hypertension was associated with more serious maternal complications 
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53. Women in ‘tight’ (vs. ‘less tight’) control were equally satisfied with their care.54 ‘Tight’ control was 
likely to be cheaper by an average of CAD$6000, based on lower neonatal care costs (p=0.07).55  
The results of the CHIPS trial are consistent with existing small trials that have shown that 
antihypertensive therapy (similar to ‘tight’ control in CHIPS), compared with no treatment or placebo 
(similar to ‘less tight’ control in CHIPS), decreases the risk of severe hypertension.22 Women enroled 
were usually without co-morbidities, and a wide variety of antihypertensive agents (started after the 
first trimester of pregnancy) were evaluated: methyldopa, labetalol, other pure beta-blockers 
(acebutolol, mepindolol, metoprolol, pindolol, and propranolol), calcium channel blockers (isradipine, 
nicardipine, nifedipine, and verapamil), hydralazine, prazosin, and ketanserin.22 This bodes well for 
women who have a contraindication to a particular medication, such as labetalol because of poorly-
controlled asthma.  
The 2018 ISSHP recommendations4 endorse commencement of antihypertensives for persistent non-
severe hypertension well before BP reaches 160/110mmHg mark, an approach that seeks to reduce the 
likelihood of developing severe maternal hypertension. An editorial pointed out that, “to manage BP 
expectantly at <160/110 mmHg but emergently at >160/110 mm Hg is logically inconsistent”; ISSHP 
supports this perspective.56 However, the American Society of Maternal-Fetal Medicine (SMFM) is 
awaiting the results of the CHAP Trial in 2020/21(NCT02299414) before advising on treatment of non-
severe chronic hypertension. CHAP is enrolling women with chronic hypertension and randomizing them 
to treatment approaches similar to CHIPS. CHAP will be powered to address whether ‘tight’ control has 
additional benefits for the mother (i.e., fewer serious maternal complications) or more side effects for 
the baby (i.e., SGA infants), but not whether there is a difference in pregnancy loss or morbidity.57  
With few exceptions, trials have initiated therapy with one antihypertensive agent. Clinicians are 
concerned about dropping BP too low, overriding knowledge that outside pregnancy, monotherapy will 
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be insufficient to control BP if it is more than 20/10mmHg above the target BP.10 In pregnancy, 
successful treatment of hypertension occurs in more than 70% of women who are primarily treated with 
one agent;22 the corresponding success rate is 30-50% outside pregnancy.  
  Choice of antihypertensive agent for BP control 
ACE inhibitors and ARBs should be discontinued once pregnancy is confirmed, because of toxic effects, 
especially renal. If used prior to pregnancy for renoprotection, there is no reasonable alternative 
available in pregnancy; it is noteworthy that most renoprotection is afforded by ‘tight’ control of BP 
using any agent. 
There is little to guide the choice of antihypertensive agent in pregnancy based on comparative trials of 
one antihypertensive agent vs. another. Meta-analysis, and subsequent small trials, have revealed no 
clear differences in maternal and perinatal outcomes.22;58-60 Compared with methyldopa, alternative 
drugs studied (i.e., beta-blockers and calcium channel blockers) may be more effective at reducing the 
risk of severe hypertension or preeclampsia. However, results for preeclampsia are inconsistent, and no 
firm conclusions can be drawn. Beta-blockers, but not calcium channel blockers, may decrease the risk 
of preeclampsia compared with placebo/no therapy; however, when beta-blockers and calcium channel 
blockers were compared directly, beta-blockers did not decrease preeclampsia as would have been 
expected. Of note, in the CHIPS Trial, women treated with methyldopa (vs. labetalol) may have had 
better maternal and perinatal outcomes, although there may have been residual confounding.61  
Methyldopa, labetalol, and nifedipine, in doses listed in Table 2, are the most commonly recommended 
antihypertensive agents in international practice guidelines, although oral labetalol is not widely 
available in low-and-middle-income countries (LMICs).62 Vitamin D has been reported to enhance the 
effectiveness of nifedipine.39 Thiazide diuretics can be considered for hypertensive women, but their use 
is limited to specific circumstances, such as medullary sponge kidney, despite concerns that they may 
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inhibit the normal plasma volume expansion of pregnancy. Thiazide use after the first trimester did not 
adversely affect maternal or perinatal outcomes, or prevent preeclampsia.63  
Some antihypertensives may be best avoided in pregnancy, although not without controversy. Atenolol 
(in contrast to other, even cardioselective, beta-blockers) may reduce fetal growth velocity;64-67 an 
inconsistent observation.68 Prazosin was associated with more stillbirths in early severe preeclampsia.69 
Oral hydralazine is not recommended because of side effects when used alone.70  
There is an unsubstantiated belief that oral methyldopa may decrease fetal alertness and movement, or 
FHR variability, and oral labetalol may decrease FHR and variability;71 prudently, changes in FHR or 
pattern should be ascribed to evolution of underlying disease, and not prescribed antihypertensive(s).  
  Postpartum antihypertensive therapy 
Blood pressure consistently rises from days 3-6 postpartum. Postpartum, hydralazine, labetalol, and 
nifedipine have been used for severe hypertension;72 all are appropriate during breastfeeding. 
Nifedipine may be more effective postnatally when administered with furosemide.40 Some ACE 
inhibitors, acceptable during breastfeeding, can be restarted after delivery (such as enalapril and 
quinapril). Captopril is effective outside pregnancy but studied postpartum only in critical care.29;31;73 
Neonatologists have reservations in babies born early or small, but there are no reports of adverse 
effects. Only two antihypertensives are not recommended for use during breastfeeding: sodium 
nitroprusside because toxic metabolites (thiocyanate and cyanide) may cross into breast milk, and oral 
clonidine because of high serum drug levels in breastfed infants.73 Information on drugs and 
breastfeeding is freely available in the LactMed database.73 
  Long-term paediatric neurodevelopmental outcomes 
The potential long-term developmental effects of antihypertensive therapy in pregnancy have been 
understudied. Most studies do not address important confounders of the relationship between 
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outcomes and antihypertensive therapy, key among which is the type of HDP. Children of women with 
gestational hypertension or preeclampsia appear to have a relatively modest, inconsistent increase in 
neurodevelopmental problems, such as inattention and externalizing behaviors (e.g., aggression), fine or 
gross motor function, or verbal ability;74-77 outcomes after chronic hypertension are unknown. Limited 
data from a few small RCTs are reassuring with regards to health or neurodevelopment at: 12-18 
months of age following nifedipine78 or atenolol,79 or 7.5 years following methyldopa.80 Data from a 
controlled observational study presented reassuring data for labetalol (N=32 pregnancies). Compared 
with women exposed to medications without known neurodevelopmental effects (N=42), children with 
in utero methyldopa exposure (N=25) had slightly lower intelligence quotient (IQ) scores within the 
normal range, related methyldopa treatment duration.81 
 
CHALLENGES AND PITFALLS RELEVANT TO THE TOPIC 
  Composite and surrogate outcomes 
Of primary interest to clinicians and women is the impact of antihypertensive therapy on maternal, fetal, 
and newborn death and serious complications. For the mother, these include death, obstetric 
complications such as abruption, and end-organ complications (such as stroke).17;82 For the fetus and 
newborn, relevant outcomes are stillbirth, neonatal death and life-threatening morbidity. Thankfully, 
these complications are individually uncommon or rare, but this situation poses a problem for 
researchers. Studying the impact of antihypertensive therapy on an individual complication (such as 
stroke) is not feasible, and even if it were, such a focus may reflect an arbitrary choice of outcome that 
does not reflect the spectrum of considerations at play. Also, the balance of benefit and risk may change 
with gestational age, as do outcomes of relevance; for example bronchopulmonary dysplasia is only 
possible if birth occurs before 32 weeks, and hypoxic-ischemic encephalopathy possible if birth occurs at 
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term. Gestational age is also important for the mother, as the implications of severe hypertension as an 
outcome are different at 25 weeks in the setting or early severe preeclampsia, compared with term, as 
the gains from pregnancy prolongation vary.  
As a response to these challenges, researchers have often studied surrogate outcomes (such as 
preeclampsia or preterm birth), or composites of rare complications. This challenge to evidence 
syntheses often results in few trials in subgroups of outcomes, and uncertainty about whether the 
effects observed are influenced by reporting biases.  
It is hoped that these challenges in outcome measurement will be addressed by the international 
movement towards standardization. Development of a core outcome dataset in preeclampsia is nearing 
completion.17  
  The unregulated use of HBPM 
Recently, HBPM has gained popularity outside pregnancy in confirming hypertension, and improving BP 
monitoring, compliance with antihypertensive medication, and achievement of BP targets.83 Compared 
with ambulatory BP monitoring, HBPM has modest diagnostic agreement, is similar in its ability to 
identify patients with ‘white coat’ effect and ‘masked’ hypertension, and is economical and comfortable. 
Distinct advantages of HBPM in pregnancy are patient engagement, and the ease with which repeat 
measurements can be obtained, especially to rule out preeclampsia superimposed on either chronic or 
gestational hypertension.84 Pregnant women and practitioners prefer HBPM to ABPM.85  
While HBPM is widely used, by more than half of hypertensive women in some studies,9 it is not widely 
appreciated by women or maternity care providers that what defines normal BP in the office (i.e., 
≥140/90mmHg) is higher than what defines normal BP at home (i.e., ≥135/85mmHg), even in pregnancy 
4;86. Also, practitioners do not usually advise women about available monitoring schedules, all of which 
involve duplicate measurements taken at least twice daily over several monitoring days.10;87 Many 
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women take it upon themselves to measure their own BP. In addition, women are not necessarily 
educated about interpretation of the values recorded, including when and whom to call about BP values 
above a given threshold.14  
  Nifedipine and magnesium sulfate co-administration 
Among women with preeclampsia among whom magnesium sulfate is indicated for eclampsia 
prevention or treatment, the risk of neuromuscular blockade (reversible with 10 g of IV calcium 
gluconate) with contemporaneous use of nifedipine and magnesium sulfate is <1%.46  
 
UNRESOLVED CLINICAL QUESTIONS 
  Nuanced antihypertensive therapy for severe and non-severe hypertension 
Although antihypertensive therapy for severe hypertension has (with few exceptions) been with 
parenteral agents other than oral (usually short-acting) nifedipine, and therapy for non-severe 
hypertension has been with oral agents, women with a HDP transition from one severity of hypertension 
to another. Severe and non-severe hypertension are not separate clinical entities, as are chronic 
hypertension and preeclampsia, for example. Clinical guidance has yet to address nuanced care 
reflecting clinical complexity or the large number of care providers. Direction about dosage escalation 
and choice of multidrug antihypertensive treatment is lacking. While, NICE guidance (UK) advises that 
oral labetalol be used as first-line therapy for hypertension of any severity, it may not be sensible to give 
a woman additional oral labetalol when she is already on 1600mg/day and presents with severe 
hypertension. 
  Personalized antihypertensive therapy 
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Outside pregnancy different mechanisms underlie essential hypertension: either high renin and 
vasoconstriction or low renin, volume-expansion.88 Patients of black race tend to fit into the low renin 
category. While this knowledge influences choice of antihypertensive outside pregnancy, there is no 
similar guidance in pregnancy. Indeed, oral labetalol is considered an acceptable first-line agent for all 
pregnant women, even in settings where the prevalence of women of black race is high (e.g., the UK). 
What about maternal hemodynamics assessment in hypertensive pregnant women? When assessed 
from the time of referral for hypertension (usually after 20 weeks’ gestation) women whose BP was 
controlled (to <140/90mmHg) with labetalol monotherapy had higher heart rate and stroke volume (and 
were less like to be of black race),89 compared with women requiring additional vasodilatory treatment 
with nifedipine.90 Those requiring the vasodilatation also experienced more severe hypertension and 
smaller babies. In 52 drug-naïve pregnant women with various hypertensive disorders (38.5% chronic), 
when initial antihypertensive therapy was guided prospectively by hemodynamics, using initial 
nifedipine therapy when vascular resistance was high or women were of black race,91 and labetalol 
otherwise to achieve BP <140/90mmHg, the incidence of severe hypertension was low (3.8%) without 
compromising fetal growth.92 Such a personalized approach based on hemodynamic assessment holds 
promise to optimize fetal growth for women receiving ‘tight’ control of BP. However, more information 
is needed about feasibility, cost implications, and effectiveness.  
  The patient voice 
Antihypertensive treatment has a clinically meaningful impact on maternal risk profiles, without 
adversely affecting the baby’s risk profile or the woman’s satisfaction with her care. However, the 
strength of recommendations is often weak and the quality of the evidence low. Therefore, optimal 
decisions about BP control will depend on how each woman trades-off (i.e., values) her own vs her 
child’s outcomes, and how those values would change depending on the gestational age at which they 
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would need to be made. Currently, we lack the data to develop patient decision aids to help clinicians 
structure information and work with women to encourage them to evaluate all decision options and 
their consequences in accordance with their values without bias, and to make a decision based on those 
trade-offs. Also, we lack the data to measure value-weighted outcomes (which would be of particular 
relevance to composite outcomes). Lastly, we need our research to priority-setting that involves input 
from all stakeholders, including women and their families, so that BP management research asks 
questions of relevance to women and measures outcomes that will inform their decision-making.  
 
CONCLUSIONS 
Internationally, antenatal care is devoted in large part to the detection of pre-eclampsia by 
measurement of BP. The withdrawal of mercury sphygmomanometers has created a major challenge for 
accurate measurement of that BP, as aneroid devices are less accurate and most automated devices 
underestimate BP in pregnancy and pre-eclampsia, specifically. When elevated BP is detected, 
regardless of the HDP, antihypertensive therapy to achieve a diastolic BP of 85mmHg will decrease 
maternal risk without increasing perinatal risk. This antihypertensive therapy will of course be 
embedded in broader, multifaceted management of the mother and fetus.  
Future work should focus on whether one antihypertensive drug offers advantages over another in 
general or for specific ethnic groups in pregnancy, and whether hemodynamic-guided antihypertensive 
therapy can optimise fetal growth and actually improve perinatal outcome. 
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Table 1: The ISSHP classification of the HDPs  
Hypertension known before 
pregnancy or before 20 weeks’ 
gestation 
Definition 
Chronic Elevated BP before pregnancy or before 20 weeks’ gestation 
Essential Without a recognized underlying cause 
Secondary Due to underlying problem, such as renal disease 
White coat hypertension Elevated BP in office/clinic, but normal BP in out-of-office 
setting (including at home) 
Masked hypertension Elevated BP in out-of-office setting, but normal BP in 
office/clinic 
Hypertension arising de novo at or 
after 20 weeks 
Definition 
Transient gestational hypertension Elevated BP documented, usually in office/clinic, but follow-
up BP measurements are normal, often in day assessment 
units or at home 
Gestational hypertension Elevated BP at ≥20 weeks’ gestation 
Pre-eclampsia 
Gestational hypertension with proteinuria or one/more 
manifestations suggestive of end-organ involvementa 
De novo 
Superimposed on chronic 
hypertension 
HDPs=hypertensive disorders of pregnancy, ISSHP=International Society for the Study of Hypertension in 
Pregnancy 
aEnd-organ involvement with pre-eclampsia includes, but is not limited to, neurological, respiratory, 
hepatic, and renal.   
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Table 2: Management of pre-eclampsia (Adapted from the Lancet5 with permission) 
Antepartum and postpartum (unless otherwise specified) 
Place of care 
Inpatient care when there is severe hypertension or maternal symptoms, 
signs, or abnormal laboratory tests 
Outpatient care can be considered, recognisizg that many women are not 
eligible and hospital re-admission rates are high following home care 
Consultation 
Obstetrics to ensure that preeclampsia risk is recognized and appropriate 
maternal and fetal surveillance is put in place 
Anesthesia to plan maternal monitoring and plan neuraxial 
analgesia/anesthesia in labour to assist with BP control and facilitate 
Cesarean delivery (should it be necessary) 
Fluid management Restrict to a maximum of 80mL/hr when an iv is in place.  
Antihypertensive 
therapy 
Severe hypertension (BP ≥160/110mmHg): 
Consider oral or parenteral agents that can be repeated in 30min if BP 
remains at ≥160 mmHg systolic or ≥110 mmHg diastolic: 
• Nifedpine capsule (10mg orally without biting to a maximum of 30mg) 
• Nifedipine tablet (10mg orally to a maximum of 30mg) 
• Hydralazine (5mg iv bolus then if needed, 5-10mg iv to a maximum of 
45mg) 
• Labetalol (20mg iv then if needed, 40mg then 80mg to a maximum of 
300mg) 
Consider alternative oral agents that can be repeated in 1 hr (supported by 
less evidence in pregnancy): 
• Labetalol (200mg orally)  
• Clonidine (0.1 - 0.2mg orally)a 
• Only postpartum - Captopril (6.25 - 12.5mg orally) 
Non-severe hypertension 
• Methyldopa (500-2000mg/d in 3 or 4 divided doses) 
• Labetalol (300-2400mg/d in 3 or 4 divided doses) 
• Nifedipine (20-120mg/d once daily) 
MgSO4 
Eclampsia treatment 
• 4g iv (over 5 min) then 1g/hr iv  
• If already on MgSO4, administer another 2-4g iv (over 5 min) and increase 
infusion to 2g/hr iv 
Eclampsia prevention among women with pre-eclampsia 
• 4g iv (over 5 min) then 1g/hr iv 
Fetal neuroprotection 
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4g iv (with/without 1g/hr until delivery or 24hr maximum) for women with 
imminent delivery at <340 weeks who do not otherwise quality for 
eclampsia prevention or treatment 
Corticosteroids 
Antenatally only, for fetal pulmonary maturity when delivery is anticipated 
within the next 7 days and at <340-6 wks 
HELLP syndrome (10mg dexamethasone IV every 12h for 48h) if 
improvement in laboratory parameters alone will change management, 
such as eligibility for neuroaxial anesthesia/analgesia or platelet 
transfusion 
Platelet transfusion for 
HELLP syndrome 
Recommended for counts: <20x109/L, 20-49x109/L prior to Cesarean, or 
≥50x109/L (± packed red blood cells) with excessive active bleeding, 
platelet dysfunction, a rapidly falling platelet count, or coagulopathy. 
HELLP=Hemolysis, Elevated Liver enzyme, Low Platelet syndrome; iv=intravenous; MgSO4=magnesium 
sulphate 
aClonidine therapy is not recommended during breastfeeding 
(http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm).  
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